Evidence map›Paper›PMID 41986383›Full record

ArticleNPJ systems biology and applications2026

Dual RAF inhibition outperforms RAF-MEK combinations for suppressing ERK signaling in KRAS mutant cells.

Hiroaki Imoto, Nora Rauch, Ayaka Ichikawa Nagasato, Mariko Okada, Walter Kolch, Oleksii S Rukhlenko, Boris N Kholodenko

Abstract read
In one paragraph

Article in NPJ systems biology and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hiroaki Imoto *Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland.
Nora Rauch *Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland.
Ayaka Ichikawa Nagasato *Laboratory for Cell Systems, Institute for Protein Research, The University of Osaka, Suita, Japan.
Mariko OkadaLaboratory for Cell Systems, Institute for Protein Research, The University of Osaka, Suita, Japan.
Walter KolchSystems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland.
Oleksii S RukhlenkoSystems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland. oleksii.rukhlenko@ucd.ie.
Boris N KholodenkoSystems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland. boris.kholodenko@ucd.ie.

Funding

Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway SignalingR01CA244660 · NCI · YALE UNIVERSITY · PI HLAVACEK, WILLIAM S, KHOLODENKO, BORIS N · 2020 to 2024
$3.4M
Fuji Foundation for Protein Research Kaneko Narita Research GrantHORIZON EUROPE Framework Programme 101136926 MULTIRJapan Science and Technology Corporation CREST Program (JPMJCR21N3)Japan Society for the Promotion of Science KAKENHI (21K15503)Japan Society for the Promotion of Science Overseas Research FellowshipsNCI NIH HHS R01 CA244660NCI NIH HHS R01CA244660Science Foundation Ireland 18/SPP/3522Science Foundation Ireland 22/PATH-S/10875
6 · The paper itself

Abstract

Complex interactions among RAS, RAF, KSR, and MEK isoforms, together with their interplay with clinically used kinase inhibitors, hinder accurate predictions of drug efficacy and the choice of optimal inhibitor combinations. Here, we combine structure-and-rule-based computational modeling with experiments to systematically study how KSR1 abundance modulates responses to RAF and MEK inhibitors (RAFi and MEKi) in PSN1 mutant KRAS

Indexed as

MAP Kinase Signaling SystemProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)raf KinasesBreast NeoplasmsCell Line, TumorFemaleHumansMCF-7 CellsMitogen-Activated Protein Kinase KinasesMutationPancreatic NeoplasmsProtein KinasesKRAS protein, humanKSR-1 protein kinaseMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProtein KinasesProto-Oncogene Proteins p21(ras)raf Kinases

Identifiers

PMID41986383
PMCPMC13357827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.